Welcome to our dedicated page for CARLSMED SEC filings (Ticker: CARL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Carlsmed, Inc. filings document the regulatory record of a commercial-stage medical technology company developing AI-enabled personalized spine surgery solutions. Recent 8-K filings report results of operations and financial condition, including furnished earnings releases tied to the company’s aprevo® platform, product activity and revenue outlook.
The company’s SEC materials also cover emerging growth company status, annual meeting and proxy governance matters, and capital-structure disclosures. Material-event filings include amendments to loan and security arrangements, credit facility terms, warrant-related disclosures and other financing matters relevant to Carlsmed’s public-company reporting.
Carlsmed, Inc. filed a current report to disclose that it has released its financial results for the quarter ended June 30, 2025. On August 28, 2025, the company issued a press release with these quarterly results, which is included as Exhibit 99.1 to the report.
The press release describing the quarter’s results is being furnished rather than filed, meaning it is not automatically subject to certain liability provisions and is not automatically incorporated into other securities filings unless specifically referenced. The company’s common stock, with a par value of $0.00001 per share, trades on The Nasdaq Stock Market LLC under the symbol CARL.